| Ali Marie Vierra, PHAMACIST | |
|
3500 Coffee Rd, Modesto, CA 95355-1305 | |
| (209) 341-0814 | |
| Not Available |
| Full Name | Ali Marie Vierra |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 3500 Coffee Rd, Modesto, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871074294 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 77106 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ali Marie Vierra, PHAMACIST 3500 Coffee Rd, Modesto, CA 95355-1305 Ph: (209) 341-0814 | Ali Marie Vierra, PHAMACIST 3500 Coffee Rd, Modesto, CA 95355-1305 Ph: (209) 341-0814 |
News Archive
BioCryst Pharmaceuticals, Inc. announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company's exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
Allos Therapeutics, Inc. today announced the presentation of initial data from COMPLETE, an international registry designed to address the urgent need for an increased understanding of the treatment patterns and outcomes for patients with peripheral T-cell lymphoma.
Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures.
TxCell SA, a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave in refractory Crohn's disease.
› Verified 1 days ago
Dr. Sujeev Vhan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3405 Mchenry Ave, T-0273, Modesto, CA 95350 Phone: 209-523-6210 | |
Cindie Masui, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1032 Oakdale Rd, Modesto, CA 95355 Phone: 209-577-6060 | |
Mrs. Truc Thanh Vo, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1101 Mchenry Ave, Modesto, CA 95350 Phone: 209-577-8695 | |
Grace Cho, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2900 Standiford Ave, Modesto, CA 95350 Phone: 209-522-1093 | |
Kenia Yulissa Medina Moreno, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1441 Florida Ave, Modesto, CA 95350 Phone: 209-576-3622 | |
Dr. Stephanie Tovar, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 Coffee Rd, Modesto, CA 95355 Phone: 209-526-4500 | |
Ashley Avila, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3801 Pelandale Ave, Modesto, CA 95356 Phone: 209-342-4902 |